Quantessence Capital LLC Takes $270,000 Position in REGENXBIO Inc. (NASDAQ:RGNX)

Quantessence Capital LLC acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 34,888 shares of the biotechnology company’s stock, valued at approximately $270,000. Quantessence Capital LLC owned about 0.07% of REGENXBIO at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of RGNX. Alpine Global Management LLC purchased a new position in REGENXBIO during the fourth quarter worth $175,000. Hsbc Holdings PLC lifted its holdings in REGENXBIO by 132.3% in the 4th quarter. Hsbc Holdings PLC now owns 84,817 shares of the biotechnology company’s stock valued at $629,000 after purchasing an additional 48,310 shares in the last quarter. Stifel Financial Corp boosted its stake in shares of REGENXBIO by 26.5% during the 4th quarter. Stifel Financial Corp now owns 188,844 shares of the biotechnology company’s stock worth $1,460,000 after purchasing an additional 39,564 shares during the last quarter. Voss Capital LP purchased a new stake in shares of REGENXBIO during the fourth quarter worth about $2,573,000. Finally, Tower Research Capital LLC TRC raised its position in shares of REGENXBIO by 442.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 13,138 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 10,714 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Price Performance

NASDAQ RGNX opened at $7.82 on Wednesday. The business’s 50-day simple moving average is $6.81 and its 200-day simple moving average is $8.11. The firm has a market capitalization of $391.91 million, a P/E ratio of -1.55 and a beta of 1.26. REGENXBIO Inc. has a 1-year low of $5.04 and a 1-year high of $17.52.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. On average, equities research analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on RGNX shares. Morgan Stanley lifted their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, March 14th. The Goldman Sachs Group dropped their target price on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, April 17th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, March 7th. Chardan Capital restated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a report on Thursday, March 20th. Finally, Leerink Partners set a $24.00 target price on shares of REGENXBIO in a research report on Tuesday, March 18th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, REGENXBIO currently has an average rating of “Moderate Buy” and an average target price of $31.63.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.